ArticleRheumatology advances in practice2025
Baseline 25-hydroxyvitamin D levels predict the effects of vitamin D supplementation on joint symptoms and cartilage loss in patients with knee osteoarthritis.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01176344 (Does Vitamin D Supplementation Prevent Progression of Knee Osteoarthritis? A Randomised Controlled Trial), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does Vitamin D Supplementation Prevent Progression of Knee Osteoarthritis? A Randomised Controlled Trial
Who cites it
2 citing papers in PubMed.
- Advances in cartilage imaging techniques.Nature reviews. Rheumatology · 2026Review
- Immunonutritional biomarkers in osteoarthritis: mechanistic insights and prognostic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To examine whether the baseline vitamin D level modifies the effects of vitamin D supplementation on knee symptoms and cartilage loss in patients with symptomatic knee OA. Methods: This was a post hoc analysis for the VIDEO study, which was a large ( Results: A total of 413 participants (mean age 63.2 years; 50% women) were randomly assigned to vitamin D and placebo groups. A baseline 25(OH)D level of 43 nmol/l was found as the cut-off value. For the total WOMAC score, vitamin D supplementation decreased more than placebo in patients with 25(OH)D levels of 12.5-43 nmol/l (-256.41 Conclusion: Supplementation of vitamin D in patients with OA who have 25(OH)D levels ≤43 nmol/l could relieve pain and improve physical function, while in OA patients with 25(OH)D levels >43 nmol/l, supplementation may ameliorate cartilage lesions. Trial registration: clinicaltrials.gov, NCT01176344; anzctr.org.au, ACTRN12610000495022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.